NCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
Clinical Trials
27 trialsNCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06228066 2026-03-23
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04802174 2026-03-17
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT06681220 2026-03-11
Relapsed SCLC
VA Office of Research and Development
Phase 1/2 Recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07459634 2026-03-10
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT05153239 2026-03-09
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Phase 3 Active not recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT07153055 2025-12-18
LOTS
Indiana University
Phase 1/2 Not yet recruiting
NCT07258147 2025-12-02
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Phase 2 Not yet recruiting
NCT05244239 2025-10-31
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Emory University
Phase 1 Recruiting
NCT07141771 2025-08-26
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Not yet recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04358237 2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2 Completed
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06501976 2024-07-15
An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06497530 2024-07-12
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Not yet recruiting
NCT04610658 2024-04-02
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT04253145 2023-11-18
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Fundacion Oncosur
Phase 1/2 Unknown
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT03213301 2021-07-14
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
Phase 2 Completed
NCT01831089 2020-04-10
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01951157 2019-09-24
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
PharmaMar
Phase 2 Completed